Updates are available Correction dated 2019-04-12
Click to view Correction: https://doi.org/10.1038/s41431-019-0394-5
-
Authors
Urreizti, Roser
Mayer, Klaus
Evrony, Gilad D.
Said, Edith
Castilla-Vallmanya, Laura
Cody, Neal A. L.
Plasencia, Guillem
Gelb, Bruce D. https://orcid.org/0000-0001-8527-5027
Grinberg, Daniel https://orcid.org/0000-0001-9859-2590
Brinkmann, Ulrich
Webb, Bryn D.
Balcells, Susanna https://orcid.org/0000-0001-6174-4677
- License Information
-
More Information
Article History
Received: 23 October 2018
Revised: 21 February 2019
Accepted: 1 March 2019
First Online: 15 March 2019
Change Date: 12 April 2019
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41431-019-0394-5
Compliance with ethical standards
:
: RU, GDE, ES, LCV, BDG, DG, BDW, and SB declare no conflict of interest. KM and UB are employees of Roche. Roche is interested in identifying novel targets and approaches for disease diagnosis and therapy. NC is an employee of Sema4, a for-profit genetic testing laboratory. GP is employed by Lead Molecular Design, SL, a company that develops software and offers modeling services for pharmaceutical industries, but has no competing interests on the results of this article.
